Under New NCI Contract, SRI International Synthesizes Compounds of Interest to Cancer Researchers.Business Editors/Health/Medical Writers MENLO PARK Menlo Park. 1 Residential city (1990 pop. 28,040), San Mateo co., W Calif.; inc. 1874. Electronic equipment and aerospace products are manufactured in the city. Menlo College and a Stanford Univ. research institute are there. 2 Uninc. , Calif.--(BUSINESS WIRE)--Nov. 4, 2003 SRI International, an independent research and development organization, has received a three-year, $1.52 million contract from the National Cancer Institute (NCI See Liberate. ) to synthesize selected chemical carcinogens Carcinogens Substances in the environment that cause cancer, presumably by inducing mutations, with prolonged exposure. Mentioned in: Colon Cancer, Rectal Cancer , derivatives of polynuclear polynuclear /poly·nu·cle·ar/ (-noo?kle-er) having several nuclei; said of cells. pol·y·nu·cle·ar or pol·y·nu·cle·ate or pol·y·nu·cle·at·ed adj. Multinuclear. aromatic hydrocarbons (PAHs), and chemopreventive agents of interest to the cancer research community. The compounds will be offered to researchers through NCI's Chemical Carcinogen carcinogen: see cancer. carcinogen Agent that can cause cancer. Exposure to one or more carcinogens, including certain chemicals, radiation, and certain viruses, can initiate cancer under conditions not completely understood. Reference Standard Repository. SRI has been one of NCI's primary synthesis contractors since the Repository's inception more than 20 years ago. Under this new contract, SRI will synthesize, isolate, purify, and characterize compounds required by researchers as authentic standards and substrates to aid in elucidation of the pathways of carcinogen metabolic activation and molecular mechanisms of action. In addition to NCI, SRI's Biosciences Division works with other government agencies and commercial pharmaceutical companies to provide a broad range of preclinical discovery and development services in a GLP See gateway location protocol. and cGMP environment. SRI's drug discoveries include the anti-malarial halofantrine (Halfan(R)), the antiviral antiviral /an·ti·vi·ral/ (-vi´ral) destroying viruses or suppressing their replication, or an agent that so acts. an·ti·vi·ral adj. vidarabine (Vira-A), several agents in human clinical trials for cancer, and several small-molecule drug candidates about to enter clinical development for cancer treatment and diagnosis. During its 50-year history of preclinical development work, SRI has performed FDA-compliant services on more than 30 marketed drugs and more than 100 drugs in clinical trials. More information about the NCI's Chemical Carcinogen Reference Standard Repository can be found at http://resresources.nci.nih.gov/database.cfm?id=382. About SRI International Silicon Valley-based SRI International (http://www.sri.com) is one of the world's leading independent research and technology development organizations. Founded as Stanford Research Institute Stanford Research Institute - Former name of SRI International. in 1946, SRI has been meeting the strategic needs of clients for more than 55 years. The nonprofit research institute performs contract research and development for government agencies, commercial businesses and nonprofit foundations. In addition to conducting contract R&D, SRI licenses its technologies, forms strategic partnerships and creates spin-off companies. SRI International is a registered trademark of SRI International. All other trademarks are the property of their respective owners. |
|
Printer friendly
Cite/link
Email
Feedback
Reader Opinion